Akademik Veri Yönetim Sistemi
34th Annual Meeting of Asian Society for Cardiovascular and Thoracic Surgery, Antalya, Türkiye, 15 - 19 Nisan 2026, ss.7, (Özet Bildiri)
Objective:
Pulmonary carcinoid tumors (PCTs) are rare neuroendocrine neoplasms of the lung, and their
preoperative diagnosis often remains challenging. Thoracic computed tomography (CT)
frequently demonstrates non-specific findings, resulting in limited diagnostic accuracy. ⁶⁸Ga-
DOTATATE positron emission tomography/computed tomography (⁶⁸Ga-PET/CT), which
targets somatostatin receptors, has emerged as a promising imaging modality for neuroendocrine
tumors. This study aimed to evaluate the diagnostic performance of ⁶⁸Ga-PET/CT in PCTs.
Methods:
In this single-center, retrospective study, 39 patients who underwent ⁶⁸Ga-PET/CT and had
histopathologically confirmed diagnoses were included. Patients were classified into three
groups according to histopathology: PCTs, benign lesions, and other pulmonary malignancies.
Quantitative ⁶⁸Ga-PET/CT parameters, including SUVmax, SUVmean, metabolic tumor volume
(MTV), total lesion glycolysis (TLG), and molecular–morphologic volume ratio (MMVR), were
statistically compared among the groups using the Kruskal–Wallis test. A p value < 0.05 was
considered statistically significant.
Results:
Of the 39 patients, 23 (59%) were diagnosed with PCTs, 13 with benign lesions, and 3 with other
pulmonary malignancies. SUVmax, SUVmean, and TLG values on ⁶⁸Ga-PET/CT were
significantly higher in the PCT group compared with the other two groups (p < 0.01, p < 0.01,
and p = 0.01, respectively). Clinicopathological characteristics according to study groups are
presented in Table 1.
Conclusion:
⁶⁸Ga PET/CT demonstrates high diagnostic discrimination for PCTs, with significantly elevated
quantitative PET parameters compared with benign and other malignant pulmonary lesions.
These findings support the use of ⁶⁸Ga-PET/CT as a valuable imaging modality in th